First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized TrialCesare Gridelli, Francesco Perrone, Fortunato Ciardiello et al.|Journal of Clinical Oncology|2012Cited by 234
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III TrialsCesare Gridelli, Francesco Perrone, Roberto Bianco et al.|Journal of Clinical Oncology|2018Cited by 70
Treatment of pulmonary neuroendocrine tumours: State of the art and future developmentsCesare Gridelli, Ferdinando Riccardi, Antônio Rossi et al.|Cancer Treatment Reviews|2012Cited by 69
Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With PembrolizumabFrancesco Jacopo Romano, Ferdinando Riccardi, Riccardo Ronga et al.|Cancer Diagnosis & Prognosis|2022Cited by 28
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung CancerMassimo Di Maïo, Cesare Gridelli, Natasha B. Leighl et al.|Journal of Thoracic Oncology|2012Cited by 26